21/05/2026 11.10-12.10 Expanding HIV prevention: PrEP, community services and real-world evidence

Sala Mizar

SC 1 **Incidence and predictors of renal toxicity among Pre-Exposure Prophylaxis users in the Italian PrIDE Cohort**

M. Menozzi[1], S. Leone[2], G. Frate[3], V. Barchi[4], E. Caruso[5], C. Tincati[6], A.M. Lucchini[7], A.M. Cattelan[8], S. Lazzarin[9], V.L. Del Negro[10], M. Ridolfi[11], M. Augello[12], M. Cernuschi[5], S. Nozza[13], C. Mussini[14], A. Antinori[15], D. Moschese[9], V. Mazzotta[4]
[1]Infectious Disease Clinia, AOU Policlinico di Modena, Modena, Italy, [2]Clinical Epidemiology and Biostatistics, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Fondazione ICONA, Milano, Italy, [4]Counseling, Test and HIV Prophylaxis and STI Unit, Regional AIDS Reference Center, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, [5]Milano Checkpoint, Milano, Italy, [6]Clinic of Infectious Diseases and Tropical Medicine, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, [7]Multidisciplinary Center for Sexual Health (Ce.Mu.S.S.), Ospedale Oftalmico "Casimiro Sperino", ASL "Città di Torino", Turin, Italy, [8]Padua University Hospital, Infectious and Tropical Diseases Unit, Padua, Italy, [9]Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [10]Checkpoint Plus Roma, Italy, [11]Department of Internal Medicine, Endocrine-Metabolic Sciences and Infectious Diseases, AOU Policlinico Umberto I, Rome, Italy, [12]Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [13]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [14]Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena; University of Modena and Reggio Emilia, School of Medicine, Modena, Italy, [15]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy

SC 2 **Prisons & community-led organizations: a fruitful collaboration to improve prevention interventions in detention facilities**

S. Penon[1], L. Cosmaro[1], S. Curridori[1], F. Falzetta[1], V. Walsh[1], A. Grisolia[2], T. Sebastiani[2], C. Cairone[2], R. Bartolotti[2], R. Ranieri[2]
[1]Fondazione LILA Milano ETS, Milan, Italy, [2]SC Direzione Coordinamento Carceri, ASST Santi Paolo e Carlo, Milan, Italy

SC 3 **Services and clinical pathways for HIV diagnosis for vulnerable populations: insights from a large HIV clinical center with hub-and-spoke network**

L. Cordier[1,2], M. Morosi[1,2], V. Iannone[2], L. Oreni[2], M.V. Cossu[2], A. Giacomelli[2,3], R. Giorgi[2], V. Micheli[4], A. Dolci[4,3], A. Gori[2,3], A. Capetti[1,2]
[1]SSD Fragilità e Prevenzione, STI Jenner44 Clinic, Milan, Italy, [2]Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, [3]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [4]Laboratory of Clinical Microbiology, Virology and Bioemergency Diagnostics, Luigi Sacco Hospital, Milan, Italy

SC 4 **Prevalence and incidence of HCV infection in a cohort of Italian PrEP users: too low to be relevant?**

A Forni[1,2], F. Peracchi[1,2], V. Brogna[1,2], A. Repishti[1,2], L. Luzi[1,2], E. Di Gennaro[1,2], G. Cavazza[1,2], M. Merli[1], N. Bana[1], C. Baiguera[1], M. Puoti[1,2], R. Rossotti[1,3]
[1]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [2]University of Milano-Bicocca, Milan, Italy, [3]University of Verona, Verona, Italy

SC 5 **First Delivery of Long-Acting Injectable (CAB-LA) Pre-Exposure prophylaxis (PrEP) in a Community-Based Setting**

V. Barchi[1], V.L. Del Negro[2], G. Del Duca[1], M. Maresca[1], G. Terracini[1], G. Frate[1], F. Cannone[1], R. Esvan[1], G. Micheli[1], C. Di Vilio[1], A. Giacinta[1], R.J. Steiner[1], S. Passacantilli[1], D. Farinacci[1], P. Faccendini[1], A. Antinori[3], V. Mazzotta[1]
[1]National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, Regional AIDS Reference Center, Rome, Italy, [2]CheckPoint PLUS Roma, Italy, [3]Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

SC 6 **Determinants of asymptomatic and symptomatic incident chlamydia and gonorrhoea infections among PrEP users**

S. Venturelli[1], G. Ghilardi[2], E. Nespoli[2], L. Comi[1], F. Borghi[1], A. Francavilla[3], D. Ripamonti[1], F. Crippa[1]
[1]Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, [2]School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, [3]FROM Research Foundation: Fondazione per la Ricerca Ospedale di Bergamo – ETS, Italy

21/05/2026 12.15-13.15 Monitoring the viral landscape

Sala Mizar

SC 7 **West Nile Virus Infections in people living with HIV in Northern Italy: a sero-repository study**

C. Castilletti[1], G. Tiecco[2], S. Accordini[1], A. Pavesi[2], N. Gianesini[1], J. Logiudice[2], R. Passarelli Mantovani[1], B. Rossi[2], F. Gobbi[1,2], L.R. Tomasoni[3], F. Castelli[2], SPARROW Group[1,2], E. Quiros-Roldan[2]
[1]Department of Infectious-Tropical Diseases and Microbiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy, [2]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, [3]Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy

SC 8 **The Disappearance of Influenza B: Epidemiological Shift and Viral Competition during the 2025-2026 Season in Genoa, Italy**

M. Lucente[1], C. Fraccalvieri[1], G. Garzillo[1], B. Galano[1], N. Nigro[1], G. Guarona[2], S. Ferrari[1], B. Giusto[1], R. Qosja[1], A. Orsi[2]
[1]U.O. Igiene, IRCCS AOM- Azienda Ospedaliera Metropolitana, Genova, Italy, [2]Dipartimento di Scienze della Salute (DiSSal), Università di Genova, Italy

SC 9 **Comparative diagnostic performance and referral burden of several anal cancer screening strategies among MSM undergoing first high-resolution anoscopy**

A. Lazzaro[1], E.N. Cavallari[1], M. Ridofi[1], F. Alessi[1], L. Santinelli[1], C. Falvino[1], L. Maddaloni[1,2], O. Turriziani[2], A. Pernazza[3], A. Crescenzi[3], C.M. Mastroianni[1], G. d'Ettorre[1]
[1]Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Roma, Italy, [2]Dipartimento di Medicina Molecolare, Laboratorio di Microbiologia e Virologia, Sapienza Università di Roma, Roma, Italy, [3]Dipartimento di Scienze Radiologiche, Oncologiche e Anatomo-Patologiche, Sapienza Università di Roma, Roma, Italy

SC 10 **Persistent HPV16 infection despite immune recovery in people living with HIV: analysis of E6 and E7 genetic variability**

S. Pauciullo[1], V. Zulian[1], R. Sciamanna[1], A. Coppola[1], M. De Sanctis[1], A. Borsellino[2], P. Del Porto[2], F. Del Nonno[3], D. Colombo[3], A. Scarabello[4], A.R. Garbuglia[1]
[1]Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), Rome, Italy, [2]Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, Rome, Italy, [3]Pathology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), Rome, Italy, [4]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), Rome, Italy

SC 11 **Low integrase resistance detected in people failing second generation INSTIs: findings from the ARCA cohort**

A. Russo[1,2], A. Giacomelli[4,5], A. De Vito[3], M. Mazzitelli[6,7,8], A. Shallvari[9], W. Gennari[10], V. Micheli[11], F. Lombardi[7,8], E. Pontali[12], S. Menzo[13], A. Carbone[7], M.C. Poliseno[14], B. Bruzzone[15], M.M. Santoro[16], A. Borghetti[17]
[1]Link Campus University, Rome, Italy, [2]Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy, [3]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [4]Department of Infectious Diseases, ASST FBF Sacco, Luigi Sacco University Hospital, Milan, Italy,[5]Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, [6]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [7]Università Cattolica del Sacro Cuore, Roma, Italia - Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Rome, Italy, [8]Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia - Dipartimento di Scienze Mediche e Chirurgiche - UOC Malattie infettive, Rome, Italy, [9]EuResist Network GEIE, InformaPRO S.r.l., Rome, Italy, [10]SSD Virologia-Microbiologia Molecolare, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, [11]Laboratory of Clinical Microbiology, Virology and Bioemergency Diagnostics, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [12]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [13]Section of Legal Medicine, Department of Bioscience and Public Health, Marche Polytechnic University, Ancona, Italy, [14]Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, [15]Hygiene Unit, IRCCS - Policlinico San Martino Hospital, Genoa, Italy, [16]Department of Experimental Medicine, University of Rome, Tor Vergata, Rome, Italy, [17]Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

SC 12 **Characteristics and phylogenetic analysis of HIV-1 sub-subtype A6 circulating/epidemic in Italy**

C. della Ventura[1], F. Saladini[2], S. Tagliazucchi[3], M. Zazzi[2], A. Gidari[4], C. Mussini[5], B. Rossetti[6], R. Gulminetti[7], P. Corsi[8], C. Lazzaretti[9], D. Segala[10], M. Fabbiani[2,11], A. Shallvari[12], S. Rusconi[1], G. Zehender[1], A. Lai[1]
[1]Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, [2]Department of Medical Biotechnology, University of Siena, Siena, Italy, [3]Molecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, [4]Infectious Diseases Laboratory, Santa Maria della Misericordia Hospital, Perugia, Italy, [5]Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy, [6]Infectious Diseases Unit, USL Toscana sud-est, Ospedale Misericordia, Grosseto, Italy, [7]Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [8]Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, [9]Infectious Diseases Unit, Arcispedale S. Maria Nuova, AULS Reggio Emilia, Reggio Emilia, Italy, [10]Department of Translational Medicine and for Romagna, Azienda Ospedaliero Universitaria di Ferrara, University of Ferrara, Ferrara, Italy, [11]Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, [12]I-PRO, Rome, Italy

21/05/2026 14.00-15.00 Shaping immune protection: vaccines, strategies across HIV and emerging infections — Sala Mizar

SC 13 **HIV-CORE 007: A phase 1/2 randomized, placebo-controlled T-cell vaccine trial in adults living with HIV-1 with analytical treatment interruption**

S. Dispinseri[1], E. Bruzzesi[1], A. Baglivi[1], S. Bagaglio[1], M. Tolazzi[1], F. Sironi[1], P. Gallina[1], D. Cesana[1], S. Chiappetta[2], F. Ciceri[1], C. Corti[1], A. Crook[3], C. Bonini[1], M. Noviello[1], E. Tassi[1], E. Tomasi[1], N. Borthwick[3], E.G.-T. Wee[3], T. Hanke[3], A. Soria[4], A. Castagna[1], R. Dell'Acqua[1], G. Scarlatti[1]
[1]IRCCS Ospedale San Raffaele, Milan, Italy, [2]Carlo Poma Hospital, ASST Mantova, Italy, [3]The Jenner Institute, University of Oxford, Oxford, United Kingdom, [4]Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

SC 14 **An extracellular vesicle-based T cell vaccine platform against HIV-1 conserved antigens**

M. Donnini, F. Manfredi, P. Leone, K. Pugliese, A. Giovannelli, M. Federico, F. Ferrantelli, C. Chiozzini
Istituto Superiore di Sanità, Rome, Italy

SC 15 **Baseline CD4 Count Influences HPV Vaccine Response in People Living With HIV: Two-Year Follow-Up**

L. Ansaldo[1,2], E. Tortellini[3], M.S. Guardiani[3,4], S. Corazza[1], A. Carraro[3], G. Mancarella[1], M. De Masi[1], D. Di Trento[1], A. Gasperin[1], M.A. Zingaropoli[3,5], F. Dominelli[3], M. Proietti[3], C. Giambi[6], M. Tagliaferro[7], U. Basile[7], R. Marocco[1], C. Del Borgo[1], M. Lichtner[4]
[1]Infectious Diseases Unit, S.M. Goretti Hospital, Latina, Italy, [2]PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome "Tor Vergata"; Roma, Italy, [3]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [4]Department of NESMOS, Sapienza University of Rome, Rome, Italy, [5]Microbiology and Virology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, [6]UOS Profilassi e sorveglianza malattie infettive, S.M. Goretti Hospital, Latina, Italy, [7]Department of Clinical Pathology, S. M. Goretti Hospital, Latina, Italy

SC 16 **Comparison of subcutaneous versus intradermal administration of MVA vaccine booster dose**

V. Mazzotta[1], L. Bordi[2], E. Cimini[3], D. Farinacci[1], S. Gili[3], A. Bettini[2], J. Paulicelli[1], R. Esvan[1], C. Mija[2], F. Cristofanelli[3], P. Faccendini[4], P. Galli[5], E. Girardi[6], F. Maggi[2], A. Antinori[1,5]
[1]Clinical department, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [2]Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Laboratory of Immunology, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [4]Pharmacy, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [5]Health Direction, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [6]Scientific Direction, INMI Lazzaro Spallanzani IRCCS, Rome, Italy

SC 17 **Vaccination coverage and adherence to vaccines in a territorial sexually transmitted infection (STI) clinic in Milan, Italy: the impact of an integrated on-site service**

F. Gullone, L. Cordier, M. Morosi, E. Beyene Teklu, C. Archetti, A. Bramati, V. Ciarutti, A. Mantineo, C. Sturniolo, E. Villa, F. Pulejo, A. Capetti
SSD Fragilità e Prevenzione – STI Clinic Jenner 44 – Department of Infectious Diseases - ASST Fatebenefratelli Sacco, Milan, Italy

SC 18 **Temporal Kinetics of Humoral and Cellular Immunity After Monoclonal Antibody Treatment for SARS-CoV -2 and Impact of Vaccination Timing: RENOIR study**

M. Camici[1], S. Meschi[2], E. Cimini[3], A. Caioli[4], J. Paulicelli[1], A. Oliva[1], M. De Vito[2], S. Gili[3], M.M. Plazzi[1], G. Micheli[1], D. Mariotti[2], G. Matusali[2], F. Cristofanelli[3], M. Fusto[1], E. Girardi[5], F. Maggi[2], A. Antinori[1,6], V. Mazzotta[1]
[1]Clinical department, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [2]Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Laboratory of Immunology, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [4]Epidemiology Unit, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [5]Scientific Direction, INMI Lazzaro Spallanzani IRCCS, Rome, Italy, [6]Health Direction, INMI Lazzaro Spallanzani IRCCS, Rome, Italy

21/05/2026 Clinical insights of Long-Acting treatment

Sala Mizar

16.10-17.10

SC 19 **Weight and Lipid Changes After Switching to Long-Acting Cabotegravir and Rilpivirine**

G. Cologgi[1], L. Taramasso[2], E. Ricci[3], S. Ferrara[4], G. Orofino[5], N. Squillace[6], E. Pontali[7], B. Menzaghi[8], E. Sarchi[9], G. Cenderello[10], G. Pellicanò[11], G. Madeddu[12], T. Bini[13], F. Lagi[14], O. Bargiacchi[15], M. Carleo[16], E. Salomoni[17], L. Pusterla[18], L. Calza[19], S. Rusconi[20], K. Falasca[21], S. Martini[22], R. Bellagamba[23], S. Piconi[24], G. De Socio[25], G. Angioni[26], A. Cascio[27], A. Di Biagio[1,2], P. Bonfanti[6] and for the CISAI study group
[1]Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, [2]Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy, [3]Fondazione ASIA, Milan, Italy, [4]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [5]Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, [6]Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, [7]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [8]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [9]Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [10]Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, [11]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, [12]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, [13]Unit of Infectious Diseases, San Paolo Hospital, Milano, Italy, [14]AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, [15]Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, [16]Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, [17]SOC 1 USL CENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, [18]Infectious Diseases Unit, Ospedale S. Anna, Como, Italy, [19]Infectious Diseases Unit, IRCCS Policlinico Sant' Orsola, University of Bologna, Italy, [20]Infectious Diseases Unit, ASST Ovest Milanese, Legnano and DIBIC, University of Milan, Italy, [21]Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy, [22]Department of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy, [23]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [24]Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, [25]Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia, Italy, [26]Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy, [27]Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

SC 20 **Use of Next-Generation Sequencing (NGS) as an Additional Tool to Evaluate Suitability of Long-Acting Cabotegravir/Rilpivirine Treatment and Tailoring Follow-Up**

G. Cologgi[1], M. Giurco[1], E. Pratolongo[1], B. Bruzzone[2], F. Stefanelli[2], N. Randazzo[2], V. Ricucci[2], M. Bassetti[1,3], A. Di Biagio[1,3], L. Taramasso[3]
[1]Department of Health Sciences, University of Genoa - Genoa, Italy, [2]Hygiene Unit, IRCCS Azienda Ospedaliera Metropolitana - Genoa, Italy, [3]Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana - Genoa, Italy

SC 21 **Virological efficacy and tolerability of the long-acting regimen with rilpivirine and cabotegravir: a quest for the ideal candidate**

G. Baldin[1], A. Ciccullo[2], F. Bassani[3], A. Giacomelli[4], A. Cervo[5], D. Moschese[4], E. Delmonte[5], F. Lagi[6], M. Rigoni[3,7], P.F. Salvo[8], M. Fabbiani[9], C. Fusetti[3], G. d'Ettorre[10], G. Madeddu[11], C. Mussini[5], A. Borghetti[12], S. Rusconi[3,7]
[1]Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy, [2]Infectious Diseases Unit, Ospedale San Salvatore, L'Aquila, Italy, [3]SC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano (MI), Italy, [4]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [5]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy, [6]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [7]Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milano, Italy, [8]Catholic University of the Sacred Heart, Rome, Italy, [9]Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, [10]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [11]Infectious Diseases Unit, University of Sassari, Sassari, Italy, [12]Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

SC 22 **Life after long-acting therapy: what happens when CAB/RPV is discontinued?**

M. Giurco[1], L. Taramasso[2], E. Ricci[3], N. Squillace[4], S. Ferrara[5], A. Parisini[6], G. Orofino[7], B. Menzaghi[8], F. Lagi[9], E. Sarchi[10], L. Pusterla[11], G. Madeddu[12], L. Calza[13], M.A. Carleo[14], G. Cenderello[15], G. Angioni[16], K. Falasca[17], E. Salomoni[18], S. Rusconi[19], G.F. Pellicanò[20], T. Bini[21], G. De Socio[22], P. Bonfanti[4], A. Di Biagio[1,2], for the CISAI study Group
[1]Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, [2]Infectious Disease Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy, [3]Fondazione ASIA, Milan, Italy, [4]Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, [5]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [6]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [7]Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, [8]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [9]AOU Infectious and Tropical Diseases, Careggi Hospital, Florence, Italy, [10]Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [11]Infectious Diseases Unit, Ospedale S. Anna, Como, Italy, [12]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, [13]Infectious disease Unit, IRCCS Policlinico Sant' Orsola, University of Bologna, Italy, [14]Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, [15]Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, [16]Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy, [17]Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy, [18]SOC 1 USLCENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, [19]Infectious Diseases Unit, ASST Ovest Milanese, Legnano and DIBIC, University of Milan, Italy, [20]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, [21]Unit of Infectious Diseases, San Paolo Hospital, Milano, Italy, [22]Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia, Italy

SC 23 **Safety of cabotegravir + rilpivirine long-acting regimen among PLWH with previous HBV exposure: preliminary results of the SCRIBE study**

N. Bana[1], F. Artelli[2,3], G. Lapadula[2,3], P. Bonfanti[2,3], P. Vitiello[4], C. Abeli[4], M. Farinazzo[4], L. Comi[5], D. Rigamondi[5], D. Valenti[1], M. Puoti[1,2], R. Rossotti[1]
[1]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [2]IRCCS San Gerardo dei Tintori, Monza, Italy, [3]School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy, [4]ASST Valle Olona, Busto Arsizio (VA), Italy, [5]ASST Papa Giovanni XXIII, Bergamo, Italy

SC 24 **Impact of cabotegravir/rilpivirine on patient-reported outcomes: real-world data from a multicenter cohort**

A. Carraro[1], R. Marocco[2], G. Mancarella[2], A. Gasperin[2], L. Ansaldo[2], M. Guardiani[3], V. Bertocchi[4], V. Serena[5,1], L. Bresciani[3], V. Speciale[3], V. Kelmendi[3], S. Iaquinandi[3], V. Filippi[1], C. Pasquazzi[1], L. Germani[1], C. Del Borgo[3,2], M. Lichtner[5,1]
[1]Infectious Diseases Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy, [2]Infectious Diseases Unit, S. M. Goretti Hospital, Polo Pontino Sapienza University of Rome, Latina, Italy, [3]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [4]Sapienza University of Rome, Rome, Italy, [5]Department of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome, Rome, Italy

22/05/2026 11.10-12.10 Innovations in HIV care: services, networks and continuity — Sala Cassiopea 2

SC 25 **People diagnosed with HIV and in care in Italy in 2024: preliminary results from the the ongoing third national survey - CARPHA3 project**

P. Piselli[1], L. Pugliese[2], V. Regine[2], E. Gennaro[1], C. Cimaglia[1], A. Caioli[1], A. Navarra[1], S. Leone[1], D. Cordella[2], C. Gubinelli[1], A. Caraglia[3], E. Girardi[1], B. Suligoi[2] and the CARPHA3 study group
[1]Istituto nazionale per le malattie infettive "L. Spallanzani" – IRCCS, Rome, Italy, [2]Istituto Superiore di Sanità, Rome, Italy, [3]Ministero della Salute, Rome, Italy

SC 26 **Searching for the denominator: preliminary findings from PRONTI project**

G. Cruschelli[1], A. Caraglia[2], F. Centrone[3], M. Chironna[4], M. Farinella[5], C. Galli[6], S. Moriconi[1], V.A. Orlando[4], C. Pasqualini[7], M. Puglia[8], L. Pugliese[9], L. Rancilio[10], V. Regine[9], F. Voller[8], L. Tavoschi[1], B. Suligoi[9]
[1]University of Pisa, Pisa, Italy, [2]Ministry of Health, Rome, Italy, [3]Policlinic of Bari, Bari, Italy, [4]University of Bari, Bari, Italy, [5]Mario Mieli, LGBTQIA+ Culture Center, Rome, Italy, [6]Independent researcher, Rome, Italy, [7]Piedmont Regional Service for the Epidemiology of Infectious Diseases (SeREMI), Alessandria, Italy, [8]Tuscany Regional Health Agency, Florence, Italy, [9]Italian National Institute of Health, Rome, Italy, [10]Caritas Ambrosiana, Milano, Italy

SC 27 **EngageHIV: a multidisciplinary model for proactive re-engagement and prevention of loss to follow-up in PLWHA**

M. Guastavigna[1], G. Orofino[1], A. Ianniello[2], A. Montalbano[3], F. Onelia[3], R. Ranotti[4], S. Scrignoli[1], G. Calleri[1]
[1]Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, [2]Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, [3]Medical Science Department, University of Turin, Turin, Italy, [4]Hospital Pharmacy, Amedeo di Savoia Hospital, Turin, Italy

SC 28 **The role of an Integrated Multidisciplinary Care Model on Continuity of Care and Immuno-Virological Outcomes in a complex population living with HIV infection**

D. Zace[1], S. Grammatico[2], V. Mazzarella[2], G. Trincia[3], L. Sarmati[1,4]
[1]Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, [2]Polo Sanitario "Villa Glori", Cooperativa Roma Solidarietà, Caritas, Rome, Italy, [3]Cooperativa Roma Solidarietà, Caritas, Rome, Italy, [4]Infectious Diseases Unit, University Hospital Tor Vergata, Rome, Italy

SC 29 **Implementation of emergency department bundled testing for HIV, HBV and HCV using residual samples: the Progresso-T project**

M. Leone[1,2], F. Cecilia[1,2], S. Ciarpaglini[1,2], E. Perugini[1,2], D. Meloni[1], L. Benedetti[1], A. Giovannelli[3,4], M. Pelagalli[3,4], F. Tomassetti[3,4], D. Zace[1], A. di Lorenzo[1,2], J.M. Legramante[1,5], C. Paganelli[5], V. Malagnino[1,2], S. Bernardini[3,4], M. Pieri[3,4], L. Sarmati[1,2], A.M. Geretti[1,2], PROGRESSO-T (Promuoviamo maggiore accesso ai test) Study Team
[1]Department of Medicine of Systems, University of Rome Tor Vergata, Rome, Italy, [2]Department of Infectious Diseases, Tor Vergata University Hospital, Rome, Italy, [3]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, [4]Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy, [5]Emergency Department, Tor Vergata University Hospital, Rome, Italy

SC 30 **Trend of number of tests for HIV in Community-Based Voluntary Counselling and Testing (CBVCT) settings in Italy (2019–2025)**

*E. Gennaro[1], C. Cimaglia[1], G. Giupponi[2], M. Farinella[3], I. Pennini[4], S. Patrucco[5], M. Cernuschi[6], L. Rancilio[7], P. Meli[8], M. Stagnitta[9], D. Masci[10], N. Frattini[11], G. Moi[12], C. Nicoara[13], S. Mattioli[14], F. Leserri[15], A. Caioli[1], S. Leone[1], A. Navarra[1], A. Caraglia[16], E. Girardi[1], P. Piselli[1] for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"**
[1]INMI L. Spallanzani, Rome, Italy, [2]LILA Milano, Milan, Italy, [3]Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, [4]Arcigay, Padua, Italy, [5]Arcobaleno AIDS, Turin, Italy, [6]Associazione Solidarietà AIDS (ASA), Milan, Italy, [7]CARITAS Ambrosiana, Milan, Italy, [8]CICA, Bergamo, Italy, [9]CNCA, Rome, Italy, [10]Fondazione Villa Maraini, Rome, Italy, [11]Milano Checkpoint, Milan, Italy, [12]Movimento Omosessuale Sardo (MOS), Sassari, Italy, [13]Network Persone Sieropostive (NPS) Italia, Milan, Italy, [14]PLUS, Bologna, Italy, [15]Checkpoint PLUS Roma, Rome, Italy, [16]Ministero della Salute, Rome, Italy

22/05/2026 Oral ART from different perspectives

Sala Mizar

14.00-15.00

SC 31 **Implementation of a same-day ART start model in a real-life setting: experiences from a clinical centre in Italy**

G. Micheli, A. Caioli, R. Esvan, A. Giacinta, V. Barchi, D. Farinacci, R.J. Steiner, N. Braccialarghe, I. Abbate, C. Pinnetti, L. Fabeni, G. Frate, G. Rozera, E. Girardi, F. Maggi, A. Antinori, V. Mazzotta
National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

SC 32 **Long-term treatment dynamics and immuno-virological recovery in advanced ART-naïve people with HIV**

A. Vergori[1], P. Borrelli[2], A. Narducci[1], I.F. Bottalico[1], S.M. Ferrara[1], C. Grillo[1], F.R.P. Ieva[1], M. Poliseno[3], A. Saracino[3], A. Cianciaruso[3], R. Schiavoni[4], L. Mezzogori[4], A. Di Biagio[4], A. Santoro[5], G.C. Marchetti[5], C. Tincati[5], S. Lo Caputo[1]
[1]Infectious Diseases Unit, A.O.U. Policlinico Foggia, University of Foggia, Foggia, Italy, [2]Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" Chieti-Pescara, Chieti, Italy, [3]Infectious Diseases Unit, A.O.U Consorziale Policlinico Bari, University of Bari, Bari, Italy, [4]Infectious Diseases Unit, IRCCS San Martino, University of Genova, Genova, Italy, [5]Infectious Diseases Unit, ASST Santi Paolo e Carlo, University of Milano Milano, Italy

SC 33 **Long-term Durability of BIC/FTC/TAF in Virologically Suppressed PWH in a Real-World Setting**

F. Lombardi[1,2], P.F. Salvo[1,2], G. Baldin[1], A. Carbone[1], G. Lenzi[2], C. De Vivo[2], E. Visconti[1], E. Tamburrini[1,2], S. Di Giambenedetto[1,2], C. Torti[1,2]
[1]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, [2]Dipartimento di Sicurezza e Bioetica sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma Italia

SC 34 **12 Months Effectiveness and safety of switching to BIC/FTC/TAF in virologically suppressed people with HIV on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL Study)**

M.V. Cossu[1], D. Moschese[1], M. Matone[1], G. Carrozzo[1], G. Pozza[1], A. Poloni[1], L. Albini[3], G. Forcina[3], A. Riva[1,2], A. Giacomelli[1,2], A. Gori[1,2,4]
[1]Department of Infectious Diseases - ASST FBF SACCO, Milan, Italy, [2]DIBIC Luigi Sacco, University of Milan, Italy [3]Gilead Sciences S.r.l – Italy, [4]Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

SC 35 **Drivers of B/F/TAF discontinuation: reflecting strategy rather than failure or toxicity**

V. Cogliandro[1], N. Squillace[1], E. Ricci[2], P. Maggi[3], L. Taramasso[4], B. Menzaghi[5], E. Sarchi[6], G.V. De Socio[7], S. Piconi[8], G.F. Pellicanò[9], T. Bini[10], G. Madeddu[11], S. Martini[12], E. Pontali[13], G. Cenderello[14], A. Bandera[15], B.M. Celesia[16], G. Orofino[17], S. Ferrara[18], M.A. Carleo[19], A. Cascio[20], A. Di Biagio[4], P. Bonfanti[1], for the CISAI Study Group
[1]Infectious Diseases Unit, IRCCS San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy, [2]Fondazione ASIA Onlus, Buccinasco (MI), Italy, [3]Infectious Diseases Unit, Università degli Studi di Enna "Kore", Italy, [4]Infectious Diseases Unit, Ospedale Policlinico San Martino – IRCCS per l'Oncologia; Department of Health's Sciences, University of Genoa, Genoa, Italy, [5]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [6]Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [7]Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, [8]Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, [9]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, Messina, Italy, [10]Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [11]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, [12]Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, [13]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [14]Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, [15]Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [16]Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, [17]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, [18]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [19]Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, [20]Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

SC 36 **Persisting Adherence Challenges in HIV Treatment: Insights from a Tertiary HIV Clinic**

E. Vania[1], F.V. Segala[1], D. Mengato[2], D. Leoni[1], S. Gardin[1], A. Ferrari[1], G. Berti[2], L. Sasset[1], A. Cattelan[1,3]
[1]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [2]Hospital Pharmacy Unit, Azienda Ospedale-Università Padova, Padua, Italy, [3]Department of Molecular Medicine, University of Padua, Padua, Italy